Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Thoma CR"'
Autor:
Schröder M; Novartis Institutes for BioMedical Research, Basel, Switzerland. martin-1.schroeder@novartis.com., Renatus M; Novartis Institutes for BioMedical Research, Basel, Switzerland.; Ridgeline Discovery, Basel, Switzerland., Liang X; Novartis Institutes for BioMedical Research, Cambridge, MA, USA., Meili F; Novartis Institutes for BioMedical Research, Cambridge, MA, USA., Zoller T; Novartis Institutes for BioMedical Research, Basel, Switzerland., Ferrand S; Novartis Institutes for BioMedical Research, Basel, Switzerland., Gauter F; Novartis Institutes for BioMedical Research, Basel, Switzerland., Li X; Novartis Institutes for BioMedical Research, Cambridge, MA, USA., Sigoillot F; Novartis Institutes for BioMedical Research, Cambridge, MA, USA., Gleim S; Novartis Institutes for BioMedical Research, Cambridge, MA, USA., Stachyra TM; Novartis Institutes for BioMedical Research, Basel, Switzerland., Thomas JR; Novartis Institutes for BioMedical Research, Cambridge, MA, USA., Begue D; Novartis Institutes for BioMedical Research, Basel, Switzerland., Khoshouei M; Novartis Institutes for BioMedical Research, Basel, Switzerland., Lefeuvre P; Novartis Institutes for BioMedical Research, Basel, Switzerland., Andraos-Rey R; Novartis Institutes for BioMedical Research, Basel, Switzerland., Chung B; Novartis Institutes for BioMedical Research, Cambridge, MA, USA., Ma R; Novartis Institutes for BioMedical Research, Cambridge, MA, USA., Pinch B; Novartis Institutes for BioMedical Research, Cambridge, MA, USA., Hofmann A; Novartis Institutes for BioMedical Research, Basel, Switzerland., Schirle M; Novartis Institutes for BioMedical Research, Cambridge, MA, USA., Schmiedeberg N; Novartis Institutes for BioMedical Research, Basel, Switzerland., Imbach P; Novartis Institutes for BioMedical Research, Basel, Switzerland., Gorses D; Novartis Institutes for BioMedical Research, Basel, Switzerland., Calkins K; Novartis Institutes for BioMedical Research, Basel, Switzerland., Bauer-Probst B; Novartis Institutes for BioMedical Research, Basel, Switzerland., Maschlej M; Novartis Institutes for BioMedical Research, Basel, Switzerland., Niederst M; Novartis Institutes for BioMedical Research, Cambridge, MA, USA., Maher R; Novartis Institutes for BioMedical Research, Cambridge, MA, USA., Henault M; Novartis Institutes for BioMedical Research, Cambridge, MA, USA., Alford J; Novartis Institutes for BioMedical Research, Cambridge, MA, USA., Ahrne E; Novartis Institutes for BioMedical Research, Basel, Switzerland., Tordella L; Novartis Institutes for BioMedical Research, Basel, Switzerland., Hollingworth G; Novartis Institutes for BioMedical Research, Basel, Switzerland., Thomä NH; Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland.; Swiss Institute for Experimental Cancer Research (ISREC), École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland., Vulpetti A; Novartis Institutes for BioMedical Research, Basel, Switzerland., Radimerski T; Novartis Institutes for BioMedical Research, Basel, Switzerland.; Ridgeline Discovery, Basel, Switzerland., Holzer P; Novartis Institutes for BioMedical Research, Basel, Switzerland., Carbonneau S; Novartis Institutes for BioMedical Research, Cambridge, MA, USA., Thoma CR; Novartis Institutes for BioMedical Research, Cambridge, MA, USA. cthoma@ridgelinediscovery.com.; Ridgeline Discovery, Basel, Switzerland. cthoma@ridgelinediscovery.com.
Publikováno v:
Nature communications [Nat Commun] 2024 Aug 19; Vol. 15 (1), pp. 7109. Date of Electronic Publication: 2024 Aug 19.
Autor:
Schröder M; Novartis Institutes for BioMedical Research, Basel, Switzerland. martin-1.schroeder@novartis.com., Renatus M; Novartis Institutes for BioMedical Research, Basel, Switzerland.; Ridgeline Discovery, Basel, Switzerland., Liang X; Novartis Institutes for BioMedical Research, Cambridge, MA, USA., Meili F; Novartis Institutes for BioMedical Research, Cambridge, MA, USA., Zoller T; Novartis Institutes for BioMedical Research, Basel, Switzerland., Ferrand S; Novartis Institutes for BioMedical Research, Basel, Switzerland., Gauter F; Novartis Institutes for BioMedical Research, Basel, Switzerland., Li X; Novartis Institutes for BioMedical Research, Cambridge, MA, USA., Sigoillot F; Novartis Institutes for BioMedical Research, Cambridge, MA, USA., Gleim S; Novartis Institutes for BioMedical Research, Cambridge, MA, USA., Stachyra TM; Novartis Institutes for BioMedical Research, Basel, Switzerland., Thomas JR; Novartis Institutes for BioMedical Research, Cambridge, MA, USA., Begue D; Novartis Institutes for BioMedical Research, Basel, Switzerland., Khoshouei M; Novartis Institutes for BioMedical Research, Basel, Switzerland., Lefeuvre P; Novartis Institutes for BioMedical Research, Basel, Switzerland., Andraos-Rey R; Novartis Institutes for BioMedical Research, Basel, Switzerland., Chung B; Novartis Institutes for BioMedical Research, Cambridge, MA, USA., Ma R; Novartis Institutes for BioMedical Research, Cambridge, MA, USA., Pinch B; Novartis Institutes for BioMedical Research, Cambridge, MA, USA., Hofmann A; Novartis Institutes for BioMedical Research, Basel, Switzerland., Schirle M; Novartis Institutes for BioMedical Research, Cambridge, MA, USA., Schmiedeberg N; Novartis Institutes for BioMedical Research, Basel, Switzerland., Imbach P; Novartis Institutes for BioMedical Research, Basel, Switzerland., Gorses D; Novartis Institutes for BioMedical Research, Basel, Switzerland., Calkins K; Novartis Institutes for BioMedical Research, Basel, Switzerland., Bauer-Probst B; Novartis Institutes for BioMedical Research, Basel, Switzerland., Maschlej M; Novartis Institutes for BioMedical Research, Basel, Switzerland., Niederst M; Novartis Institutes for BioMedical Research, Cambridge, MA, USA., Maher R; Novartis Institutes for BioMedical Research, Cambridge, MA, USA., Henault M; Novartis Institutes for BioMedical Research, Cambridge, MA, USA., Alford J; Novartis Institutes for BioMedical Research, Cambridge, MA, USA., Ahrne E; Novartis Institutes for BioMedical Research, Basel, Switzerland., Tordella L; Novartis Institutes for BioMedical Research, Basel, Switzerland., Hollingworth G; Novartis Institutes for BioMedical Research, Basel, Switzerland., Thomä NH; Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland.; Swiss Institute for Experimental Cancer Research (ISREC), École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland., Vulpetti A; Novartis Institutes for BioMedical Research, Basel, Switzerland., Radimerski T; Novartis Institutes for BioMedical Research, Basel, Switzerland.; Ridgeline Discovery, Basel, Switzerland., Holzer P; Novartis Institutes for BioMedical Research, Basel, Switzerland., Carbonneau S; Novartis Institutes for BioMedical Research, Cambridge, MA, USA., Thoma CR; Novartis Institutes for BioMedical Research, Cambridge, MA, USA. cthoma@ridgelinediscovery.com.; Ridgeline Discovery, Basel, Switzerland. cthoma@ridgelinediscovery.com.
Publikováno v:
Nature communications [Nat Commun] 2024 Jan 04; Vol. 15 (1), pp. 275. Date of Electronic Publication: 2024 Jan 04.
Autor:
Vulpetti A; Global Discovery Chemistry, Novartis Institutes for BioMedical Research, Basel 4002, Switzerland., Holzer P; Global Discovery Chemistry, Novartis Institutes for BioMedical Research, Basel 4002, Switzerland., Schmiedeberg N; Global Discovery Chemistry, Novartis Institutes for BioMedical Research, Basel 4002, Switzerland., Imbach-Weese P; Global Discovery Chemistry, Novartis Institutes for BioMedical Research, Basel 4002, Switzerland., Pissot-Soldermann C; Global Discovery Chemistry, Novartis Institutes for BioMedical Research, Basel 4002, Switzerland., Hollingworth GJ; Global Discovery Chemistry, Novartis Institutes for BioMedical Research, Basel 4002, Switzerland., Radimerski T; Oncology Drug Discovery, Novartis Institutes for BioMedical Research, Basel 4002, Switzerland., Thoma CR; Oncology Drug Discovery, Novartis Institutes for BioMedical Research, Basel 4002, Switzerland., Stachyra TM; Oncology Drug Discovery, Novartis Institutes for BioMedical Research, Basel 4002, Switzerland., Wojtynek M; Chemical Biology & Therapeutics, Novartis Institutes for BioMedical Research, Basel 4002, Switzerland., Maschlej M; Chemical Biology & Therapeutics, Novartis Institutes for BioMedical Research, Basel 4002, Switzerland., Chau S; Chemical Biology & Therapeutics, Novartis Institutes for BioMedical Research, Basel 4002, Switzerland., Schuffenhauer A; Chemical Biology & Therapeutics, Novartis Institutes for BioMedical Research, Basel 4002, Switzerland., Fernández C; Chemical Biology & Therapeutics, Novartis Institutes for BioMedical Research, Basel 4002, Switzerland., Schröder M; Chemical Biology & Therapeutics, Novartis Institutes for BioMedical Research, Basel 4002, Switzerland., Renatus M; Chemical Biology & Therapeutics, Novartis Institutes for BioMedical Research, Basel 4002, Switzerland.
Publikováno v:
ACS medicinal chemistry letters [ACS Med Chem Lett] 2023 Jun 02; Vol. 14 (7), pp. 949-954. Date of Electronic Publication: 2023 Jun 02 (Print Publication: 2023).
Autor:
Hauseman ZJ; Novartis Institutes for BioMedical Research, Cambridge, MA, USA. zachary.hauseman@novartis.com., Fodor M; Novartis Institutes for BioMedical Research, Cambridge, MA, USA., Dhembi A; Novartis Institutes for BioMedical Research, Cambridge, MA, USA., Viscomi J; Novartis Institutes for BioMedical Research, Cambridge, MA, USA., Egli D; Novartis Institutes for BioMedical Research, Basel, Switzerland., Bleu M; Novartis Institutes for BioMedical Research, Basel, Switzerland., Katz S; Novartis Institutes for BioMedical Research, Basel, Switzerland., Park E; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA.; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA., Jang DM; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA.; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA., Porter KA; Novartis Institutes for BioMedical Research, Cambridge, MA, USA., Meili F; Novartis Institutes for BioMedical Research, Cambridge, MA, USA., Guo H; Novartis Institutes for BioMedical Research, Cambridge, MA, USA., Kerr G; Novartis Institutes for BioMedical Research, Basel, Switzerland., Mollé S; Novartis Institutes for BioMedical Research, Basel, Switzerland., Velez-Vega C; Novartis Institutes for BioMedical Research, Cambridge, MA, USA., Beyer KS; Novartis Institutes for BioMedical Research, Basel, Switzerland., Galli GG; Novartis Institutes for BioMedical Research, Basel, Switzerland., Maira SM; Novartis Institutes for BioMedical Research, Basel, Switzerland., Stams T; Novartis Institutes for BioMedical Research, Cambridge, MA, USA., Clark K; Novartis Institutes for BioMedical Research, Cambridge, MA, USA., Eck MJ; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA.; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA., Tordella L; Novartis Institutes for BioMedical Research, Basel, Switzerland. luca.tordella@novartis.com., Thoma CR; Novartis Institutes for BioMedical Research, Cambridge, MA, USA. claudio.thoma@novartis.com., King DA; Novartis Institutes for BioMedical Research, Cambridge, MA, USA. dan.king@novartis.com.
Publikováno v:
Nature [Nature] 2022 Sep; Vol. 609 (7926), pp. 416-423. Date of Electronic Publication: 2022 Jul 13.
Autor:
Weisberg E; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. ellen_weisberg@dfci.harvard.edu.; Department of Medicine, Harvard Medical School, Boston, MA, USA. ellen_weisberg@dfci.harvard.edu., Chowdhury B; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medicine, Harvard Medical School, Boston, MA, USA., Meng C; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Case AE; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Ni W; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medicine, Harvard Medical School, Boston, MA, USA., Garg S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medicine, Harvard Medical School, Boston, MA, USA., Sattler M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medicine, Harvard Medical School, Boston, MA, USA., Azab AK; Washington University in Saint Louis School of Medicine, St. Louis, MO, USA., Sun J; Washington University in Saint Louis School of Medicine, St. Louis, MO, USA., Muz B; Washington University in Saint Louis School of Medicine, St. Louis, MO, USA., Sanchez D; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Toure A; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Stone RM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medicine, Harvard Medical School, Boston, MA, USA., Galinsky I; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Winer E; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medicine, Harvard Medical School, Boston, MA, USA., Gleim S; Novartis Pharma AG, Basel, Switzerland., Gkountela S; Novartis Pharma AG, Basel, Switzerland., Kedves A; Novartis Pharma AG, Basel, Switzerland.; Alphina Therapeutics, Westport, CT, USA., Harrington E; Novartis Pharma AG, Basel, Switzerland., Abrams T; Novartis Pharma AG, Basel, Switzerland., Zoller T; Novartis Pharma AG, Basel, Switzerland., Vaupel A; Novartis Pharma AG, Basel, Switzerland., Manley P; Novartis Pharma AG, Basel, Switzerland., Faller M; Novartis Pharma AG, Basel, Switzerland., Chung B; Novartis Pharma AG, Basel, Switzerland., Chen X; Novartis Pharma AG, Basel, Switzerland., Busenhart P; Novartis Pharma AG, Basel, Switzerland., Stephan C; Novartis Pharma AG, Basel, Switzerland., Calkins K; Novartis Pharma AG, Basel, Switzerland., Bonenfant D; Novartis Pharma AG, Basel, Switzerland., Thoma CR; Novartis Pharma AG, Basel, Switzerland., Forrester W; Novartis Pharma AG, Basel, Switzerland., Griffin JD; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. james_griffin@dfci.harvard.edu.; Department of Medicine, Harvard Medical School, Boston, MA, USA. james_griffin@dfci.harvard.edu.
Publikováno v:
Blood cancer journal [Blood Cancer J] 2022 Jul 19; Vol. 12 (7), pp. 110. Date of Electronic Publication: 2022 Jul 19.
Autor:
Pinch BJ; Novartis Institutes for BioMedical Research, Cambridge, MA 02139, USA. Electronic address: benika.pinch@novartis.com., Buckley DL; Novartis Institutes for BioMedical Research, Cambridge, MA 02139, USA., Gleim S; Novartis Institutes for BioMedical Research, Cambridge, MA 02139, USA., Brittain SM; Novartis Institutes for BioMedical Research, Cambridge, MA 02139, USA., Tandeske L; Novartis Institutes for BioMedical Research, Emeryville, CA 94608, USA., D'Alessandro PL; Novartis Institutes for BioMedical Research, Basel, Switzerland., Hauseman ZJ; Novartis Institutes for BioMedical Research, Cambridge, MA 02139, USA., Lipps J; Novartis Institutes for BioMedical Research, Cambridge, MA 02139, USA., Xu L; Novartis Institutes for BioMedical Research, Cambridge, MA 02139, USA., Harvey EP; Novartis Institutes for BioMedical Research, Cambridge, MA 02139, USA., Schirle M; Novartis Institutes for BioMedical Research, Cambridge, MA 02139, USA., Sprague ER; Novartis Institutes for BioMedical Research, Cambridge, MA 02139, USA., Forrester WC; Novartis Institutes for BioMedical Research, Cambridge, MA 02139, USA. Electronic address: william.forrester@novartis.com., Dovala D; Novartis Institutes for BioMedical Research, Emeryville, CA 94608, USA. Electronic address: dustin.dovala@novartis.com., McGregor LM; Novartis Institutes for BioMedical Research, Cambridge, MA 02139, USA. Electronic address: lynn.mcgregor@novartis.com., Thoma CR; Novartis Institutes for BioMedical Research, Cambridge, MA 02139, USA. Electronic address: claudio.thoma@novartis.com.
Publikováno v:
Cell chemical biology [Cell Chem Biol] 2022 Jan 20; Vol. 29 (1), pp. 57-66.e6. Date of Electronic Publication: 2021 Sep 08.
Autor:
Schukur L; Novartis Institutes for Biomedical Research (NIBR) Oncology, Novartis, Basel, Switzerland. lina.schukur@roche.com.; Pharmaceutical Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Switzerland. lina.schukur@roche.com., Zimmermann T; Novartis Institutes for Biomedical Research (NIBR) Oncology, Novartis, Basel, Switzerland., Niewoehner O; NIBR Chemical Biology and Therapeutics, Novartis, Cambridge, USA., Kerr G; Novartis Institutes for Biomedical Research (NIBR) Oncology, Novartis, Basel, Switzerland., Gleim S; NIBR Chemical Biology and Therapeutics, Novartis, Cambridge, USA., Bauer-Probst B; Novartis Institutes for Biomedical Research (NIBR) Oncology, Novartis, Basel, Switzerland., Knapp B; NIBR Chemical Biology and Therapeutics, Novartis, Cambridge, USA., Galli GG; Novartis Institutes for Biomedical Research (NIBR) Oncology, Novartis, Basel, Switzerland., Liang X; NIBR Chemical Biology and Therapeutics, Novartis, Cambridge, USA., Mendiola A; Genomics Institute of the Novartis Research Foundation, LaJolla, USA., Reece-Hoyes J; NIBR Chemical Biology and Therapeutics, Novartis, Cambridge, USA., Rapti M; Novartis Institutes for Biomedical Research (NIBR) Oncology, Novartis, Basel, Switzerland., Barbosa I; Novartis Institutes for Biomedical Research (NIBR) Oncology, Novartis, Basel, Switzerland., Reschke M; Novartis Institutes for Biomedical Research (NIBR) Oncology, Novartis, Basel, Switzerland., Radimerski T; Novartis Institutes for Biomedical Research (NIBR) Oncology, Novartis, Basel, Switzerland.; Basilea Pharmaceutica, Basel, Switzerland., Thoma CR; NIBR Chemical Biology and Therapeutics, Novartis, Cambridge, USA. claudio.thoma@novartis.com.
Publikováno v:
Scientific reports [Sci Rep] 2020 Nov 18; Vol. 10 (1), pp. 20044. Date of Electronic Publication: 2020 Nov 18.
miR-28-5p promotes chromosomal instability in VHL-associated cancers by inhibiting Mad2 translation.
Autor:
Hell MP; Authors' Affiliations: Institute of Molecular Health Sciences; and Rodent Center HCI, ETH Zurich, Zurich, Switzerland., Thoma CR, Fankhauser N, Christinat Y, Weber TC, Krek W
Publikováno v:
Cancer research [Cancer Res] 2014 May 01; Vol. 74 (9), pp. 2432-43. Date of Electronic Publication: 2014 Feb 03.
Autor:
Thoma CR; Institute of Molecular Health Sciences, ETH Zurich, 8093 Zurich, Switzerland. Electronic address: claudio.thoma@biol.ethz.ch., Zimmermann M; Institute of Molecular Health Sciences, ETH Zurich, 8093 Zurich, Switzerland., Agarkova I; InSphero AG, 8952 Schlieren, Switzerland., Kelm JM; InSphero AG, 8952 Schlieren, Switzerland., Krek W; Institute of Molecular Health Sciences, ETH Zurich, 8093 Zurich, Switzerland. Electronic address: wilhelm.krek@biol.ethz.ch.
Publikováno v:
Advanced drug delivery reviews [Adv Drug Deliv Rev] 2014 Apr; Vol. 69-70, pp. 29-41. Date of Electronic Publication: 2014 Mar 15.
Autor:
Smole Z; Authors' Affiliations: Institute of Molecular Health Sciences, ETH Zurich, Zurich, Switzerland; and Department of Cell Biology, The Scripps Research Institute, La Jolla, California., Thoma CR, Applegate KT, Duda M, Gutbrodt KL, Danuser G, Krek W
Publikováno v:
Cancer research [Cancer Res] 2014 Jan 01; Vol. 74 (1), pp. 353-62. Date of Electronic Publication: 2013 Nov 26.